10 Tips for Choosing a Dietary Supplement OEM

Dietary supplements are often judged by the promise on the label. Yet a reliable product begins much earlier, with the partner that formulates, sources, and manufactures it. Choosing a Dietary Supplement OEM is not simply a price comparison. It means checking whether a company can turn a clear product brief into consistent batches, supported by practical quality controls. Small details matter. Ask how ingredients are identified, how specifications are approved, and how finished batches are tested. Request examples of records, not just polished claims. A neat brochure is not evidence.

The right questions can reveal strengths and gaps before a project reaches production. Review the OEM’s experience with your format, such as capsules, powders, or gummies. Discuss minimum order quantities, lead times, packaging options, and how changes are documented. Confirm which quality standards and testing practices apply to your product and intended markets; requirements can vary. Look for clear communication when a supplier cannot meet a request. That honesty can be more useful than a fast yes. Even careful screening cannot remove every risk. It can, however, make decisions more informed and reduce avoidable surprises. The ten tips below offer a practical framework for comparing suppliers, assessing evidence, and choosing a partner whose capabilities fit your product goals. Some questions may feel repetitive. Ask them anyway.

Table of Contents [Hide]

1 Set Product Scope Under the 1994 DSHEA Framework

2 Audit FDA 21 CFR Part 111 cGMP Systems and Records

3 Check Formulation Skills Against the 75-Day NDI Notice Rule

4 Compare Testing for Identity, Strength, Purity, and Contaminants

5 Verify Stability, Labeling, and 15-Business-Day Safety Reporting

Set Product Scope Under the 1994 DSHEA Framework

Under the 1994 Dietary Supplement Health and Education Act (DSHEA), a supplement’s intended use shapes its product scope. Before approaching an OEM, define the target user, dosage form, proposed ingredients, and purpose. A two-capsule daily serving, for example, creates different formulation and labeling needs than a flavored powder. Keep it narrow.

In the United States, dietary supplements generally do not receive FDA approval before marketing. The responsible company must ensure the product and its labeling meet applicable requirements. Structure/function claims, such as “supports digestive health,” need substantiation and require the DSHEA disclaimer on the label. Claims to diagnose, treat, cure, or prevent disease can place a product in drug territory. Wording matters.

Ask the OEM how it reviews ingredient status, specifications, and proposed claims before production. Some new dietary ingredients require a notification to FDA at least 75 days before marketing, subject to statutory exceptions. Request clear records for identity, purity, strength, and manufacturing controls; a polished sample alone proves little. Teams sometimes settle a label claim too early, then discover the evidence does not support it. That happens. Have qualified regulatory professionals review the intended use and label, especially when ingredients or claims change. The scope may need revision.

Audit FDA 21 CFR Part 111 cGMP Systems and Records

Review an OEM’s FDA 21 CFR Part 111 cGMP system in practice, not just on paper. Ask how quality staff approve component specifications, production instructions, and finished-product release. Trace one lot from receiving through shipment, checking dates, initials, test results, and material reconciliations. Records should tell a clear story. Missing signatures or unexplained edits deserve follow-up.

Tip: Request an appropriately redacted batch production record and compare it with the master manufacturing record. Check training logs, equipment cleaning records, deviation investigations, and corrective actions. Ask who can stop a batch when results fall outside specifications. Small details matter.

Walk through the facility with quality staff and observe whether daily practices match written procedures. Review how electronic records preserve access controls and audit trails, where applicable. A polished binder can conceal gaps in routine work, and one visit cannot prove consistent performance. Treat unclear answers as open questions; note what evidence would resolve them.

Check Formulation Skills Against the 75-Day NDI Notice Rule

A capable dietary supplement OEM should know when a formulation may involve a new dietary ingredient, not just how to blend it. In the United States, an ingredient generally falls into this category if it was not marketed in the country before October 15, 1994. Some ingredients may be exempt, so check the evidence rather than relying on a sales claim.

Ask the OEM to assess each ingredient’s history and keep supporting records. These might include dated product labels, supplier specifications, and documents showing how the ingredient was used. Ask for the paper trail. Also discuss whether a change in dose, extraction method, or ingredient combination could affect the assessment. Details matter here.

If an NDI notification is required, it must be submitted to FDA at least 75 days before the ingredient is introduced, or delivered for introduction, into interstate commerce. FDA receipt is not the same as FDA approval. That distinction matters. Ask who will prepare the notification, review the safety rationale, and track timing. A good partner should explain uncertainties plainly; even experienced teams can misread old marketing records. Have qualified regulatory counsel review the plan before production begins.

10 Tips for Choosing a Dietary Supplement OEM — Check Formulation Skills Against the 75-Day NDI Notice Rule

#	Evaluation Area	What to Ask or Verify	Useful Evidence	Why It Matters for NDI Review
1	Ingredient status assessment	Can the OEM assess each dietary ingredient’s identity and whether it may qualify as a new dietary ingredient (NDI)?	Ingredient identity records, supplier specifications, and a written ingredient-status assessment.	An NDI is generally a dietary ingredient not marketed in the United States before October 15, 1994. The assessment should be ingredient-specific, not based only on the finished product name.
2	75-day notification planning	Can the OEM build regulatory review and submission lead time into the product launch schedule?	A development timeline showing the proposed notification date and planned marketing date.	When a notification is required, the FDA must receive it at least 75 days before the product containing the NDI is introduced or delivered for introduction into interstate commerce.
3	Safety evidence support	Can the OEM assemble relevant safety information for the proposed ingredient, intended use, and serving conditions?	Safety studies, published literature, use-history documentation, and a clearly organized evidence file.	An NDI notification must include the basis for concluding that the ingredient is reasonably expected to be safe under the conditions of use described in the notification.
4	Formulation and exposure details	Can the OEM document ingredient amounts, serving size, frequency of use, and the intended consumer group?	Master formula, product specifications, directions for use, and exposure calculations.	Safety evaluation depends on the proposed conditions of use. A change in dose, use pattern, or target population can affect the relevance of the supporting evidence.
5	Manufacturing process control	Can the OEM explain how processing, extraction, purification, and storage are controlled?	Process flow, raw-material specifications, batch records, and testing procedures.	Manufacturing details help establish what the ingredient is and whether the safety information applies to the ingredient as actually produced.
6	Ingredient and supplier traceability	Can each ingredient lot be traced to its source and linked to the finished-product batch?	Certificates of analysis, lot records, supplier qualification files, and traceability procedures.	Reliable identity and quality records support accurate ingredient descriptions and help substantiate the information used in a safety assessment.
7	Change management	Does the OEM review changes to ingredient source, specifications, manufacturing, dose, or intended use before implementation?	Documented change-control procedure and examples of regulatory impact assessments.	A material change may affect the product’s identity, safety rationale, or whether an existing notification remains relevant. Regulatory review should precede launch of a changed product.
8	Regulatory role clarity	Will the OEM state in writing who is responsible for determining whether a notification is needed and preparing or submitting it?	Contract language, responsibility matrix, and a defined document-approval process.	Not every dietary supplement requires an NDI notification. The responsible parties should assess the facts for each ingredient and intended use; hiring an OEM does not itself resolve that obligation.
9	Quality systems and records	Can the OEM provide records showing how it controls production, testing, deviations, and complaints?	Quality procedures, batch documentation, testing records, and audit information.	Appropriate manufacturing controls help ensure that the commercial product matches the formulation and specifications described in the supporting documentation.
10	Regulatory communications and launch readiness	Can the OEM track FDA correspondence and prevent launch before the applicable notice period has elapsed?	Submission correspondence, a regulatory calendar, and a documented launch-release checklist.	An NDI notification is not FDA approval. A clear review process helps distinguish submission from approval and keeps launch timing aligned with the statutory notice period.

Compare Testing for Identity, Strength, Purity, and Contaminants

When comparing dietary supplement OEMs, ask what each test actually measures and whether results apply to the finished product. A credible certificate of analysis should identify the batch, test methods, specifications, and actual results—not just say “pass.” Check identity testing carefully. For botanicals, methods such as chromatography can help distinguish the intended plant from lookalikes or substitution. Strength testing should quantify the declared active ingredients or nutrients in the finished batch. Look beyond the label claim.

Purity testing checks whether the ingredient or product meets defined quality specifications. Contaminant screening should reflect the raw materials and manufacturing risks, and may include heavy metals, microbes, pesticides, or residual solvents. Ask how samples are collected, how often testing occurs, and whether methods are validated for that product. Independent laboratory testing can add useful verification, but it does not replace clear sampling records or sensible specifications. Read the details. A polished certificate can still leave gaps, especially if it covers only incoming ingredients rather than finished batches. I would treat unclear methods or missing batch results as reasons to ask more questions, not as proof of poor quality.

Verify Stability, Labeling, and 15-Business-Day Safety Reporting

Tip 1: Ask the OEM for stability data tied to your exact formula, packaging, and storage conditions. A powder in a sealed pouch may behave differently from the same blend in a clear bottle. Review the test schedule, methods, and results—not just a stated shelf life. Ask what happens when a batch trends outside its limits. Keep the records.

Tip 2: Check that the label matches the approved formula and serving directions. Compare ingredient names, amounts, allergen statements, and warnings against the master documents. Confirm who reviews artwork and who approves changes before printing. A clean-looking label can still contain an outdated detail. I have seen checklists help, though they are easy to rush.

Tip 3: Clarify safety reporting before production begins. Ask who receives consumer complaints, how serious events are escalated, and who submits required reports within 15 business days where applicable. Put the clock’s starting point, responsible contact, and backup contact in writing. Test the process with a sample report. It may feel fussy. Better to find a missing phone number during a drill than during a real incident.

Dietary Supplement OEM Checks: Key U.S. Reporting Timelines

Verify that your OEM has procedures for both deadlines: serious adverse event reports must be submitted to FDA within 15 business days of receipt, and FDA must be notified within 30 days after a structure/function claim is first marketed. The chart shows the stated deadlines; business days and calendar days are different units.

Sources: FDA serious adverse event reporting · FDA structure/function claims

10 Tips for Choosing a Dietary Supplement OEM

Set Product Scope Under the 1994 DSHEA Framework

Audit FDA 21 CFR Part 111 cGMP Systems and Records

Check Formulation Skills Against the 75-Day NDI Notice Rule

10 Tips for Choosing a Dietary Supplement OEM — Check Formulation Skills Against the 75-Day NDI Notice Rule

Compare Testing for Identity, Strength, Purity, and Contaminants

Verify Stability, Labeling, and 15-Business-Day Safety Reporting

Dietary Supplement OEM Checks: Key U.S. Reporting Timelines

Article Source:

View Products

Our Locations

Visit Us in CT, NY & CA